businesspress24.com - Critical Outcome Technologies Inc. Issues Share Options
 

Critical Outcome Technologies Inc. Issues Share Options

ID: 1150125

(firmenpresse) - LONDON, ONTARIO -- (Marketwire) -- 09/11/12 -- Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT) announced today that an employee and a consultant were each granted 200,000 share options from the Company's Stock Option Plan as part of the compensation under their respective employment and consulting agreements on September 10, 2012. These 400,000 options have a life of five years and are exercisable at a price of $0.14 per share with vesting occurring immediately. The exercise price represents the closing price of the Company's common shares on Friday, September 7, 2012, the last reported trade on the TSX Venture Exchange prior to the approval date.

About Critical Outcome Technologies Inc. (COTI)

COTI is a leading-edge company specializing in accelerating the discovery of small molecules thus enabling new drugs to be brought to market in a more cost effective, efficient and timely manner. COTI'S proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds most likely to be successfully incorporated in disease-specific drug discovery, as well as subsequent optimization and preclinical development. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, please visit our website .

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Contacts:
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
519-858-5157


Critical Outcome Technologies Inc.
Gene Kelly
Chief Financial Officer
519-858-5157




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  MethylGene Presents MGCD290 Data at the 2012 Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Critical Outcome Technologies and Delmar Chemicals Sign Collaboration Agreement to Identify and Develop Novel Small Molecules
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 11.09.2012 - 14:05 Uhr
Sprache: Deutsch
News-ID 1150125
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

LONDON, ONTARIO


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 167 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Critical Outcome Technologies Inc. Issues Share Options
"
steht unter der journalistisch-redaktionellen Verantwortung von

Critical Outcome Technologies Inc. (COTI) (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Critical Outcome Technologies Inc. (COTI)



 

Who is online

All members: 10 567
Register today: 2
Register yesterday: 0
Members online: 0
Guests online: 95


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.